Meta Pixel

News and Announcements

2OPAL announces partnership with Choco Up, Asia’s leading revenue-based financing investor

  • Published October 07, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Opal is one of the first licensed neo banks in Asia offering the full suite of financial solutions focused on international commerce and trade – multi-currency wallets, payments, financing & growth capital, escrow and collections from across 180 countries. Users can access a marketplace of solution providers through a single dashboard.

Opal, a neo-bank licensed by the Monetary Authority of Singapore (MAS), is announcing its partnership with a financing partner, Choco Up, the leading revenue-based financing investor in Asia.

Opal, a Major Payment Institution (MPI) licensed by the Monetary Authority of Singapore (MAS), is announcing its partnership with a financing partner, Choco Up, the leading revenue-based financing investor in Asia. Together, they will offer a range of financing solutions to e-commerce and digital companies, the most unique of which, is revenue-based financing (“RBF”). RBF is unique in the region as applicants only need to repay a percentage of their revenue. The solution matches the applicant’s revenue numbers as it can grow and ebb to reduce pressure on their cash flow. There is also one flat fee making the cost of financing truly transparent. It takes 30 seconds to register for an account and get a preliminary offer in 5 minutes.

As long as companies use Opal to receive payments, giving visibility into their receivables, the qualification criteria for the RBF is easier and the fee is less. Users get multi-currency accounts, financing, and payments on a single Opal account.

Connect with the company and learn more about OPAL by accessing their deal room here.

Register Interest

Capital Insights
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula

Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.

Join over 45,000+ sophisticated investors

Join Now